Investor Relations

Financial Releases

Date Title and Summary Additional Formats
Toggle Summary Intersect ENT Reports Preliminary Fourth Quarter and Full Year 2018 Revenue
MENLO PARK, Calif. --(BUSINESS WIRE)--Jan. 7, 2019-- Intersect ENT, Inc.  (NASDAQ: XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported preliminary unaudited revenue for the fourth quarter and full year ended  December 31,
View HTML
Toggle Summary Intersect ENT Announces First Patient Enrolled in ASCEND Study of Investigational Drug-Coated Sinus Balloon
Innovative Drug-Device Combination Will Leverage Company’s Expertise in Localized Drug Delivery MENLO PARK, Calif. --(BUSINESS WIRE)--Dec. 17, 2018-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced the
View HTML
Toggle Summary Intersect ENT to Present at the 37th Annual J.P. Morgan Healthcare Conference
MENLO PARK, Calif. --(BUSINESS WIRE)--Dec. 11, 2018-- Intersect ENT, Inc. (Nasdaq: XENT ), today announced that management will participate in the 37 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019 at the Westin St. Francis Hotel in San Francisco , and will present at 4:30
View HTML
Toggle Summary Intersect ENT Announces Publication of Pooled Analysis of Steroid Releasing Implants in Patients Following Frontal Sinus Surgery
MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 15, 2018-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced publication of a pooled analysis in the International Forum of Allergy & Rhinology , the official
View HTML
Toggle Summary Intersect ENT to Present at the Piper Jaffray 30th Annual Healthcare Conference
MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 7, 2018-- Intersect ENT, Inc. (Nasdaq:XENT) today announced that management will participate in the 30 th Annual Piper Jaffray Health Care Conference on November 28 at the Lotte New York Palace in New York City , and will present in a session at 10:30am ET
View HTML
Toggle Summary Intersect ENT Reports Third Quarter 2018 Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 5, 2018-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the third quarter ended September 30, 2018 .
View HTML
Toggle Summary Intersect ENT Announces Executive Team Appointments
Christine Kowalski Joins as Chief Operations Officer; Susan Stimson Named Chief Strategy Officer MENLO PARK, Calif. --(BUSINESS WIRE)--Oct. 29, 2018-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today
View HTML
Toggle Summary Intersect ENT to Report Third Quarter 2018 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Oct. 17, 2018-- Intersect ENT, Inc. (NASDAQ:XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that it will release third quarter financial results on November 5, 2018 .
View HTML
Toggle Summary Intersect ENT Reports Second Quarter 2018 Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Aug. 1, 2018-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the second quarter ended June 30, 2018 .
View HTML
Toggle Summary Intersect ENT to Report Second Quarter 2018 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Jul. 11, 2018-- Intersect ENT, Inc. (NASDAQ: XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that it will release financial results for its second quarter on August 1, 2018 .
View HTML